started · updated
Clinicians weigh data and payer requirements in lung cancer immunotherapy selection
Medical professionals are navigating complex factors when selecting first-line immunotherapy regimens for non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (SCLC). In NSCLC, clinicians rely on clinical data, established habits, and patient-specific factors such as PD-L1 levels and genetic markers like KEAP1 or STK11. However, payer requirements are increasingly influencing treatment plans, sometimes forcing clinicians to choose specific PD-1 inhibitors based on insurance preferences.
For extensive-stage SCLC, the choice between regimens like those from the CASPIAN and IMpower133 trials often comes down to modest differences in survival data and the flexibility of chemotherapy backbones. One significant deciding factor is whether an immunotherapy agent carries indications for both limited-stage and extensive-stage disease, which allows for greater simplicity in a patient's long-term treatment journey.
Entities
Caspian · CheckMate 9LA · IMpower133 · KEYNOTE-189 · KEYNOTE-407